The PRIMAVERA Study: Reduxine Safety Monitoring in Patients With Alimentary Obesity

Completed

Brief Summary: The aim of this study is to summarize the data on efficacy and safety of Reduxine administration in the routine clinical practice according to the approved indications.

Detailed Description: Secondary objectives:

* to study the structure of the population of patients with the diet induced obesity with body mass index (BMI) 30 kg/m2 or diet induced obesity with BMI ≥27 kg/m2 associated with type 2 diabetes mellitus in respect of comorbidities and concomitant treatment to determine the areas for further investigations.

* to introduce the elements of control of adverse cardiovascular risks into the routine clinical practice: questionnaire concerning enrollment criteria for Reduxine treatment initiation, algorithm of Reduxine administration and treatment efficacy and safety monitoring (assessment schedule).

* to assess the effects of the treatment of overweight and obesity with Reduxine on patients' quality of life parameters.

The Time Frame: the follow up of the study patients will be performed during six month to one year. Exception - premature discontinuation from the study.

The scheduled visits of the patients to the investigational centres are: Week0 (inclusion of the patient), Week 2, 4, 6, 8, 10, 12, 16, 20, 24, 36 and Week 48.

Recruitment & Eligibility

Inclusion Criteria

Men and women of 18-65 years of age to whom, in the doctor's opinion, the on-label use of Reduxine is indicated.
Patient's desire and ability to participate in the program and fulfill the doctor's instructions designed to achieve the treatment goal and the program requirements compliance.
Signed informed consent form for participation in the program.

Exclusion Criteria

Current or the history of:

coronary artery disease (e.g. angina, myocardial infraction);
congestive heart failure;
tachycardia;
peripheral arterial occlusive disease;
arrythmia;
Uncontrolled arterial hypertension >145/90 mm Hg;
Hypersensitivity to sibutramine or any components of Reduxine®;
Current use of monoamineoxidase inhibitors (IMAO) or their use within the last 2 weeks;
Current use of other central acting weight reducing drugs or their use within the last 2 weeks;
Use on other drugs affecting the central nervous system (e.g. antidepressants, neuroleptics); tryptophan-containing drugs indicated for sleep disturbance;
Severe eating disorder (anorexia nervosa or bulimia);
Mental disease;
Gilles de la Tourette syndrome (generalized tics);
Body mass index ≤30 kg/m2 or ≤27 kg/m2 in the presence of concomitant diseases (dyslipidemia, diabetes);
Organic cause of obesity (e.g. hypothyrosis);
Thyrotoxicosis;
Sever liver and/or kidney function abnormality;
Benign prostatic hyperplasia;
Phaeochromocytoma;
Narrowangle glaucoma;
Documented pharmacologic, drug or alcohol addiction;
Pregnancy and lactation;
Refusal to sign the informed consent form for participation in the program;
Participation in a clinical study of any new drug product within 90 days prior to the screening visit.

Primary Outcome Measures

Name	Time	Method
Body Weight Loss After 3, 6 & 12 Month Treatment	Baseline, after 3, 6 and 12 months of treatment.	Patients were weighed at each visit, but the statistical data processing was carried out after 3, 6 and 12 months of treatment.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Adverse Events	From the 1st day of Reduxine treatment until the end of the treatment	Percentage of participants with all adverse events since the start of the Reduxine treatment to the end of the study